Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: A time for excitement and equipoise Journal Article
| Authors: | Azzoli, C. G.; Park, B. J.; Pao, W.; Zakowski, M.; Kris, M. G. |
| Article Title: | Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: A time for excitement and equipoise |
| Abstract: | In patients with previously-untreated, completely-resected pathologic stage II-III non-small cell lung cancer, 4 months of postoperative cisplatin-based chemotherapy reduces the risk of death by approximately 20%. To date, the only prospectively validated prognostic and predictive factor which can be used to guide clinical practice is pathologic stage. Higher stage patients have a worse prognosis, but derive more benefit from adjuvant chemotherapy. Numerous molecular markers are being developed with the potential to help decide which patients to treat with adjuvant chemotherapy, and which drugs to use. This paper will review the molecular markers which are having immediate impact on treatment decisions in routine practice, and which merit further study in the next generation of adjuvant chemotherapy trials. © 2008International Association for the Study of Lung Cancer. |
| Keywords: | treatment outcome; survival analysis; cancer surgery; dna-binding proteins; proto-oncogene proteins; fatigue; review; cisplatin; erlotinib; patient selection; antineoplastic agents; clinical trials as topic; gemcitabine; cancer adjuvant therapy; chemotherapy, adjuvant; follow-up studies; neoplasm staging; anorexia; treatment indication; biomarkers; infection; anemia; beta tubulin; lung non small cell cancer; nausea; carcinoma, non-small-cell lung; lung neoplasms; peripheral neuropathy; epidermal growth factor receptor; fas ligand; tumor markers, biological; randomized controlled trials as topic; calcium; hemoglobin; excision repair cross complementing protein 1; time factors; docetaxel; protein tyrosine kinase inhibitor; febrile neutropenia; molecular marker; rna; albumin; dna; cyclin dependent kinase inhibitor 1b; adjuvant chemotherapy; intracellular signaling peptides and proteins; ras protein; lactate dehydrogenase; ras proteins; navelbine; k ras protein; tubulin; non-small cell lung cancer; oncogene ras; multidrug resistance-associated proteins; molecular markers; hair loss; guanosine triphosphatase; p27kip1; genes, erbb-1; membrane transport proteins; vein disease; egfr (epidermal growth factor receptor); ercc1 (excision repair cross-complementation group 1); kras (kirsten rat sarcoma viral oncogene homolog); multidrug resistance protein 2; endonucleases |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 3 |
| Issue: | 1 |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2008-01-01 |
| Start Page: | 84 |
| End Page: | 93 |
| Language: | English |
| DOI: | 10.1097/JTO.0b013e31815efe24 |
| PUBMED: | 18166846 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 10" - "Export Date: 17 November 2011" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work